Himadri Speciality Chemical announced strong Q1 results with a 27% profit jump and approved significant capex. The ₹368 crore investment aims to boost high-value specialty products, including India's first Carbon Nano Tubes facility. This move signals a strategic shift towards advanced materials.
Himadri Speciality Chemical Approves ₹368 Crore Capex, Q1 Profit Rises 27%
Consolidated Q1 Revenue: ₹1431.88 crore
Consolidated Q1 Net Profit: ₹228.43 crore
Reader Takeaway: Strong financial growth meets strategic expansion into high-value materials.
What just happened
Himadri Speciality Chemical reported its financial results for the quarter ending June 30, 2026. The company saw a significant increase in revenue and net profit compared to the previous year. Concurrently, the Board of Directors greenlit three substantial capital expenditure projects totaling ₹368 crore. These investments are focused on expanding the company's capacity in high-value specialty products and are planned to be funded mainly through internal accruals.
Why this matters
The strong financial performance indicates healthy business operations. The approved capex projects signal a strategic move towards more profitable, niche products like Carbon Nano Tubes (CNT) and Super Speciality Carbon Black. This diversification aims to reduce reliance on commodity chemicals and enhance long-term value realization, potentially leading to improved margins for shareholders.
The backstory
Himadri Speciality Chemical has been gradually increasing its focus on specialty products. The current capex plans are a significant step in this direction, building on in-house research and development. The company's strategy involves shifting its product mix towards higher-margin segments.
What changes now
With the board's approval, the company will proceed with the implementation of the three capex projects. This includes expanding Anthraquinone and Carbazole capacity, establishing India's first CNT manufacturing facility, and setting up a Super Speciality Carbon Black production unit. These developments are expected to unfold over the next few years, with commissioning dates ranging from Q2FY27 to Q4FY28.
Risks to watch
Key risks include potential delays in project execution and commissioning, as well as market acceptance and competitive pressures for the new, high-value products. Ensuring smooth integration and operational efficiency for these advanced facilities will be critical.
Peer comparison
While specific peer capex announcements for similar advanced materials are not detailed in the filing, Himadri's move into CNT production positions it as a pioneer in India. Competitors in specialty carbon black and Anthraquinone/Carbazole may exist, but the company is aiming for differentiation through these specific expansions.
Context metrics (time-bound)
The company reported consolidated revenue of ₹1431.88 crore for the quarter ended June 30, 2026, a rise from ₹1118.29 crore in the same period last year. Net profit increased to ₹228.43 crore from ₹179.36 crore year-over-year. Basic EPS grew to ₹4.55 from ₹3.68.
What to track next
Investors should closely monitor the progress and timelines of the three capex projects, particularly the commissioning of the CNT facility by Q4FY27 and the Super Speciality Carbon Black unit by Q4FY28. Tracking the revenue contribution and profitability from these new ventures will be crucial.